See the DrugPatentWatch profile for Ozanimod
When does Ozanimod’s patent protection expire?
Ozanimod’s patent expiry depends on which specific patent(s) cover the drug and which country’s filings you mean. Patent protection is handled patent-by-patent (not as one single “expiry date” for the whole product), and different jurisdictions also have different rules for term adjustments and patent-life extensions.
The provided information does not include Ozanimod’s specific patent numbers, jurisdictions, filing dates, or granted/active status, so a precise expiry date cannot be determined from what’s been shared.
How can I find the exact expiry date for ozanimod in a specific country?
To get an accurate expiry date, you typically need to identify:
- The country (e.g., US, EP, UK, JP)
- The controlling patent family covering ozanimod (often multiple patents across composition, formulations, and uses)
- Whether any supplementary protection certificates (SPCs) or patent term adjustments apply (common in Europe; different mechanisms in the US)
- Whether patents are challenged, partially invalidated, or already expired
The most reliable source is the patent register for that jurisdiction (for example, USPTO in the US or EPO/ national registers in Europe), combined with the drug’s marketed-product reference.
Why is there sometimes more than one “expiry” date for the same drug?
Ozanimod can have multiple overlapping patents, so “expiry” can mean different things:
- Patent(s) that expire first (allowing certain generics/biosimilars routes, if allowed by regulation)
- Later patents (e.g., specific formulations or methods of use) that can keep protection in place
- Regulatory exclusivities that can delay market entry even after some patents expire, depending on the country and product type
Without the specific patent set and jurisdiction, it’s easy to end up with conflicting dates.
What does patent expiry affect for competitors?
Patent expiry (and the timing of it) affects when other companies can enter the market with:
- Generics (where chemically synthesized versions are allowed)
- “Orange Book” style challenges (in the US, for small-molecule drugs) or equivalent mechanisms in other regions
- Generic launches that may be timed around the “last effective” patent, not the first
Exact timing again depends on which patents remain in force at the time of entry.
If you tell me the country, I can narrow it down
If you share either:
- the country you care about (US vs EU vs UK vs another), or
- the patent numbers / a link to the patent record you’re looking at,
I can help you interpret what the controlling expiry date would be for ozanimod in that jurisdiction.
Sources
No sources were provided with the question, so no citations are included.